ProCE Banner Activity

Phase II LURET Study: Vandetanib Monotherapy Active in RET-Rearranged Advanced NSCLC

Slideset Download
Conference Coverage
Treatment-experienced patients with rare RET-fusion driver mutations responded well to single-agent vandetanib in this small trial, with more than one half of patients achieving an objective response.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals